NCT02299765View on ClinicalTrials.gov

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

PHASE4TerminatedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Interventions
DRUG

Gefitinib

patients in arm A will be given gefitinib as target therapy

DRUG

gemcitabine

patients in arm A will be given gemcitabine chemotherapy

DRUG

carboplatin

patients in arm A will be given carboplatin chemotherapy

Trial Locations (1)

610000

China West Hospital, Chengdu

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Sichuan University

OTHER